tucaresol has been researched along with Anemia, Sickle Cell in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arya, R; Bellingham, AJ; Posner, J; Rolan, PE; Wootton, R | 1 |
| Nash, GB; Stone, PC; Stuart, J | 1 |
| Johnson, CS; Keidan, AJ; Marwah, SS; Sowter, MC; Stuart, J | 1 |
1 trial(s) available for tucaresol and Anemia, Sickle Cell
| Article | Year |
|---|---|
Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzaldehydes; Benzoates; Erythrocytes; Hemoglobin, Sickle; Hemolysis; Humans; L-Lactate Dehydrogenase; Oxygen | 1996 |
2 other study(ies) available for tucaresol and Anemia, Sickle Cell
| Article | Year |
|---|---|
Substituted benzaldehydes (12C79 and 589C80) that stabilize oxyhaemoglobin also protect sickle cells against calcium-mediated dehydration.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Benzoates; Calcium; Dehydration; Erythrocytes, Abnormal; Humans; Oxyhemoglobins; Potassium | 1992 |
Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease.
Topics: Anemia, Sickle Cell; Benzaldehydes; Benzoates; Erythrocyte Deformability; Hemoglobin, Sickle; Humans; Oxygen | 1989 |